UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Reversal of Alzheimer's-Like Pathology and Behavior in Human APP Transgenic Mice by Mutation of Asp664

Proceedings of the National Academy of Sciences - PNAS, 2006-05, Vol.103 (18), p.7130-7135

2006

Link zum Volltext

Verfügbarkeit prüfen

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Nature (London), 2001-11, Vol.414 (6860), p.212-216

2001

Link zum Volltext

Verfügbarkeit prüfen

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production

Nature medicine, 2005-05, Vol.11 (5), p.545-550

2005

Link zum Volltext

Verfügbarkeit prüfen

The role of Rho in G protein-coupled receptor signal transduction

Annual review of pharmacology and toxicology, 2000-01, Vol.40 (1), p.459-489

2000

Link zum Volltext

Verfügbarkeit prüfen

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

The Journal of clinical investigation, 2003-08, Vol.112 (3), p.440-449

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals

Alzheimer disease and associated disorders, 2007-10, Vol.21 (4), p.292-299

2007

Link zum Volltext

Verfügbarkeit prüfen

Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein

The Journal of biological chemistry, 2011-11, Vol.286 (46), p.39794-39803

2011

Link zum Volltext

Verfügbarkeit prüfen

Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain

The Journal of biological chemistry, 2003-08, Vol.278 (33), p.30748-30754

2003

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of Rho‐kinase modulate amyloid‐β (Aβ) secretion but lack selectivity for Aβ42

Journal of neurochemistry, 2006-01, Vol.96 (2), p.355-365

2006

Link zum Volltext

Verfügbarkeit prüfen

Rho‐mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2

Journal of neurochemistry, 2004-10, Vol.91 (2), p.501-512

2004

Link zum Volltext

Verfügbarkeit prüfen

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

The Journal of clinical investigation, 2003-08, Vol.112 (3), p.440-449

2003

Link zum Volltext

Verfügbarkeit prüfen

Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.31831-31837

2003

Link zum Volltext

Verfügbarkeit prüfen

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.31831-31837

2003

Link zum Volltext

Verfügbarkeit prüfen

The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.31825-31830

2003

Link zum Volltext

Verfügbarkeit prüfen

Physical and Functional Interactions of Gαq with Rho and Its Exchange Factors

The Journal of biological chemistry, 2001-01, Vol.276 (18), p.15445-15452

2001

Link zum Volltext

Verfügbarkeit prüfen

The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.31825-31830

2003

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of Rho-kinase modulate amyloid- beta (A beta ) secretion but lack selectivity for A beta 42

Journal of neurochemistry, 2006-01, Vol.96 (2), p.355-365

2006

Link zum Volltext

Verfügbarkeit prüfen

A subset of NSAIDs lower anyloidogenic Abeta42 independently of cyclooxygenase activity

Nature (London), 2001-11, Vol.414 (6860), p.212-216

2001

Link zum Volltext

Verfügbarkeit prüfen

The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of ÎºB Kinase, and NFÎºB, Do Not Reduce Amyloid Î²42 Production

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.31825

2003

Link zum Volltext

Verfügbarkeit prüfen

NSAIDs and enantiomers of flurbiprofen target [gamma]-secretase and lower A[beta]42 in vivo

The Journal of clinical investigation, 2003-08, Vol.112 (3), p.440

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

Alzheimer disease and associated disorders, 2007-10, Vol.21 (4), p.292

2007

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42

Journal of neurochemistry, 2006-01, Vol.96 (2), p.355

2006

Link zum Volltext

Verfügbarkeit prüfen

Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain

The Journal of biological chemistry, 2003-08, Vol.278 (33), p.30748

2003

Link zum Volltext

Verfügbarkeit prüfen

AÎ²42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain

The Journal of biological chemistry, 2003-08, Vol.278 (33), p.30748

2003

Link zum Volltext

Verfügbarkeit prüfen

O4-05-03: A key role of the C-terminal cleavage of APP in Alzheimer’s disease

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S85-S85

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(74)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(76)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Humans
(30)
Life Sciences & Biomedicine
(25)
Female
(15)
Animals
(12)
Male
(11)
Multidisciplinary Sciences
(9)
Science & Technology - Other Topics
(9)
Anti-Inflammatory Agents, Non-Steroidal - Pharmacology
(8)
Biochemistry & Molecular Biology
(8)
Neurology
(8)
Proteins
(8)
Adult
(7)
Patients
(7)
Biological And Medical Sciences
(6)
Mice
(6)
Multidisciplinary
(6)
Alzheimer's Disease
(5)
Amyloid Beta-Protein Precursor - Metabolism
(5)
Amyloid Precursor Protein Secretases
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reversal of Alzheimer's-Like Pathology and Behavior in Human APP Transgenic Mice by Mutation of Asp664

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production

The role of Rho in G protein-coupled receptor signal transduction

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals

Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein

Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain

Inhibitors of Rho‐kinase modulate amyloid‐β (Aβ) secretion but lack selectivity for Aβ42

Rho‐mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 Production

Physical and Functional Interactions of Gαq with Rho and Its Exchange Factors

The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production

Inhibitors of Rho-kinase modulate amyloid- beta (A beta ) secretion but lack selectivity for A beta 42

A subset of NSAIDs lower anyloidogenic Abeta42 independently of cyclooxygenase activity

The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of ÎºB Kinase, and NFÎºB, Do Not Reduce Amyloid Î²42 Production

NSAIDs and enantiomers of flurbiprofen target [gamma]-secretase and lower A[beta]42 in vivo

Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals

Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42

Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain

AÎ²42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain

O4-05-03: A key role of the C-terminal cleavage of APP in Alzheimer’s disease

Suchergebnisse filtern